Журнал "Медицинский совет" №9/2020

DOI: 10.21518/2079-701X-2020-9-16-24

  Д.И. Юдин¹, e-mail: yudinden@mail.ru,  К.К. Лактионов^1,2,  К.А. Саранцева¹,  О.И. Борисова¹,   В.В. Бредер¹,  Е.В. Реутова¹,  М.Ф. Белоярцева¹,  С.Ю. Крутелева¹,  И.А. Джанян¹

¹ Национальный медицинский онкологический центр им. Н.Н. Блохина; ² Российский национальный исследовательский медицинский университет им. Н.И. Пирогова

В последнее время ингибиторы иммунных контрольных точек существенно изменили возможности терапии рака во всем мире. Постоянно увеличивается количество препаратов этой группы и показаний к их применению. В настоящий момент в Российской Федерации зарегистрированы и используется целый ряд ингибиторов иммунных контрольных точек: анти-PD1 (ниволумаб, пембролизумаб), анти-PD-L1 (атезолизумаб, дурвалумаб), анти-CTLA-4-моноклональные антитела (ипилимумаб). Одним из наиболее распространенных осложнений иммунотерапии является иммуноопосредованная эндокринопатия. По данным клинических исследований частота развития серьезных эндокринных иммуноопосредованных нежелательных явлений в целом при монотерапии анти-PD1-моноклональными антителами невелика и составляет 3,5–8%. Однако применение анти-CTLA4-препаратов, комбинированных режимов, проведение иммунотерапии после химиолучевой терапии значительно повышают частоту развития серьезных нежелательных явлений до 30%. В реальной клинической практике иммуноопосредованная эндокринопатия была выявлена у 22 из 245 пациентов (8,9%), получавших иммунотерапию в химиотерапевтическом отделении №17 НМИЦ онкологии им. Н.Н. Блохина по поводу немелкоклеточного рака легкого и гепатоцеллюлярного рака. У большинства пациентов развились нежелательные явления 1–2-й степени, у двух – 3-й степени, что потребовало прекращения лечения. Данная статья имеет своей целью предоставить полезную информацию и дать рекомендации практическим онкологам относительно коррекции часто встречающихся вариантов иммуноопосредованной эндокринопатии (в том числе гипотиреоза, гипертиреоза, гипофизита, надпочечниковой недостаточности).

Для цитирования:

Юдин Д.И., Лактионов К.К., Саранцева К.А., Борисова О.И., Бредер В.В., Реутова Е.В., Белоярцева М.Ф., Крутелева С.Ю., Джанян И.А. Иммуноопосредованная эндокринопатия у пациентов на фоне лечения ингибиторами контрольных точек. Медицинский Совет. 2020;(9):16-24. https://doi.org/10.21518/2079-701X-2020-9-16-24

Конфликт интересов: авторы заявляют об отсутствии конфликта интересов.

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

 Denis I. Yudin¹, e-mail: yudinden@mail.ru,  Konstantin K. Laktionov^1,2,  Ksenia A. Sarantseva¹,  Olga I. Borisova¹, Valeriy V. Breder¹,  Elena V. Reutova¹, Maria F. Beloyartseva¹,  Svetlana Yu. Kruteleva¹,  Irina A. Dzhanyan¹

¹ N.N. Blokhin National Medical Research Center of Oncology; ² Pirogov Russian National Research Medical University

Recently immune checkpoint inhibitors amazingly changed the landscape of cancer therapy worldwide. The number of immune checkpoint molecules in clinical practice is constantly increasing. There are some monoclonal antibodies recently registered in the Russian Federation: anti-PD1 antibodies (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab), anti-CTLA-4 (ipilimumab). Immune-mediated endocrinopathies are some of the most common complications of immunotherapy. According to the results of clinical studies, the incidence of serious endocrine immuno-mediated adverse events with anti-PD1 monoclonal antibodies is low (3.5–8%). The use of anti-CTLA4 antibodies, combined regimens, and the use of immunotherapy after chemoradiotherapy significantly increase the incidence of serious adverse events to 30%. In clinical practice of N.N. Blokhin Cancer Research Center among 245 non-small cell lung cancer and hepatocellular carcinoma patients treated with immunotherapy, 22 (8,9%) developed an immune-mediated endocrinopathy. Most patients developed adverse events of 1–2 degrees, in two patients – 3 degrees, requiring discontinuation of treatment. The aim of this article was to provide useful information and recommendations regarding the management of common immuno-related endocrine adverse events (including hypothyroidism, hyperthyroidism, pituitary, adrenal insufficiency) for clinical oncologists.

For citation:

Yudin D.I., Laktionov K.K., Sarantseva K.A., Borisova O.I., Breder V.V., Reutova E.V., Beloyartseva M.F., Kruteleva S.Yu., Dzhanyan I.A. Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors. Meditsinskiy sovet = Medical Council. 2020;(9):16-24. (In Russ.) https://doi.org/10.21518/2079-701X-2020-9-16-24

Conflict of interest: the authors declare that there is no conflict of interest.

Загрузить файл в формате PDF

Список литературы / References

1. 
   
2. Horn L., Gettinger S.N., Gordon M.S., Herbst R.S., Gandhi L., Felip E. et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018;101:201-209. https://doi.org/10.1016/j.ejca.2018.06.031.
   
3. Antonia S.J., Borghaei H., Ramalingam S.S., Horn L., de Castro Carpeño J., Pluzanski A. et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395-1408. https://doi.org/10.1016/S1470-2045(19)30407-3.
   
4. Gettinger S., Horn L., Jackman D., Spigel D., Antonia S., Hellmann M. et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced NonSmall-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018;36(17):1675-1684. https://doi.org/10.1200/JCO.2017.77.0412.Fogt S., Shustova M., Demidov L.V., Moiseyenko V., Tjulandin S., Semiglazova T. et al. Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma.. J Clin Oncol. 2019;37(15):9549. https://doi.org/10.1200/JCO.2019.37.15_suppl.9549.
   
5. Vaishampayan U., Schöffski P., Ravaud A., Borel C., Peguero J., Chaves J. et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):275. https://doi.org/10.1186/s40425-019-0746-2.
   
6. Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachern M.P., Shen L.Y. et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1. https://doi.org/10.1186/s40842-018-0073-4.
   
7. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. https://doi.org/10.1038/nrc3239.
   
8. Weber J., Mandala M., del Vecchio M., Gogas H.J., Arance A.M., Cowey C.L. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824-1835. https://doi.org/10.1056/NEJMoa1709030.
   
9. Garon E.B., Hellmann M.D., Rizvi N.A., Carcereny E., Leighl N.B., Ahn M.J. et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518-2527. https://doi.org/10.1200/JCO.19.00934.
   
10. Hellmann M.D., Ciuleanu T.-E., Pluzanski A., Lee J.S., Otterson G.A., AudigierValette C. et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093-2104. https://doi.org/10.1056/NEJMoa1801946.
    
11. Mok T.S.K., Wu Y.L., Kudaba I., Kowalski D.M., Cho B.C., Turna H.Z. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7.
    
12. Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301. https://doi.org/10.1056/NEJMoa1716948.
    
13. Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R. et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929. https://doi.org/10.1056/NEJMoa1709937.
    
14. Morganstein D.L., Lai Z., Spain L., Diem S., Levine D., Mace C. et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017;86(4):614-620. https://doi.org/10.1111/cen.13297.
    
15. Robert C., Joshua A.M., Kefford R., Joseph R.W., Wolchok J.D., Hodi F.S. et al. Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. Journal of Clinical Oncology. 2015;33(15):9050. https://doi.org/10.1200/jco.2015.33.15_suppl.9050.
    
16. McMillen B., Dhillon M.S., Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016;2016:10.1136/bcr-214603. https://doi.org/10.1136/bcr-2016-214603.
    
17. Win M.A., Thein K.Z., Qdaisat A., Yeung S.J. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med. 2017;35(7):1039.e5-1039.e7. https://doi.org/10.1016/j.ajem.2017.02.048.
    
18. Trinh B., Sanchez G.O., Herzig P., Läubli H. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J Immunother Cancer. 2019;7(1):52. https://doi.org/10.1186/s40425-019-0528-x.
    
19. Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S., Min L., Krop I.E., Tolaney S.M. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Metaanalysis. JAMA Oncol. 2018;4(2):173-182. https://doi.org/10.1001/jamaoncol.2017.3064.
    
20. Paepegaey A.C., Lheure C., Ratour C., Lethielleux G., Clerc J., Bertherat J. et al. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. J Endocr Soc. 2017;1(6):646-649. https://doi.org/10.1210/js.2017-00170.
    
21. Dillard T., Yedinak C.G., Alumkal J., Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29-38. https://doi.org/10.1007/s11102-009-0193-z.
    
22. Torino F., Barnabei A., De Vecchis L., Salvatori R., Corsello S.M. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012;17(4):525-535. https://doi.org/10.1634/theoncologist.2011-0404.
    
23. Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361-1375. https://doi.org/10.1210/jc.2012-4075.
    
24. Blansfield J.A., Beck K.E., Tran K., Yang J.C., Hughes M.S., Kammula U.S. et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593-598. https://doi.org/10.1097/01. cji.0000178913.41256.06.
    
25. Albarel F., Gaudy C., Castinetti F., Carré T., Morange I., Conte-Devolx B. et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195-204. https://doi.org/10.1530/EJE-14-0845.
    
    
26. Min L., Hodi F.S., Giobbie-Hurder A., Ott P.A., Luke J.J., Donahue H. et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin Cancer Res. 2015;21(4):749-755. https://doi.org/10.1158/1078-0432.CCR-14-2353.
    
27. Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J. et al. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. J Clin Endocrinol Metab. 2018;103(2):365-369. https://doi.org/10.1210/jc.2017-01905.
    
28. Barroso-Sousa R., Ott P.A., Hodi F.S., Kaiser U.B., Tolaney S.M., Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018;124(6):1111-1121. https://doi.org/10.1002/cncr.31200.
    
29. Clotman K., Janssens K., Specenier P., Weets I., De Block C.E.M. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018;103(9):3144-3154. https://doi.org/10.1210/jc.2018-00728.
    
30. Shamy T.A., Aguasvivas M., Serhan M., Fojas M.M. Diabetic Ketoacidosis Triggered by Pembrolizumab in a Patient with Bladder Cancer. Diabetes. 2018;67(1):219-LB. https://doi.org/10.2337/db18-219-LB.
    
31. Maamari J., Yeung S.J., Chaftari P.S. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med. 2019;37(2):376.e1-376.e2. https://doi.org/10.1016/j.ajem.2018.10.040.